All In Biotech

Drug Trial Radar · NCT07281781

Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Sep 16, 2025

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
University of California, IrvineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/II protocol investigating whether Nelfinavir can improve anemia and lower serum fibrosis biomarkers in Myelofibrosis patients.

Conditions

  • Myelofibrosis
  • Myelofibrosis; Anemia

Interventions

  • NelfinavirDrug

    Taken twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Hepcidin LevelsTime frame: 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chao Family Comprehensive Cancer Center, University of California, Irvine

    Orange, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.